Bacterial outer membrane vesicles as a platform for biomedical applications: An update

被引：268
作者：
Li, Min [1 ,2 ]
Zhou, Han [2 ]
Yang, Chen [2 ]
Wu, Yi [2 ]
Zhou, Xuechang [1 ]
Liu, Hang [2 ]
Wang, Yucai [2 ]
机构：
[1] Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen 518060, Guangdong, Peoples R China
[2] Univ Sci & Technol China, Div Mol Med, Hefei Natl Lab Phys Sci Microscale, CAS Key Lab Innate Immun & Chron Dis,Sch Life Sci, Hefei 230027, Anhui, Peoples R China
来源：
JOURNAL OF CONTROLLED RELEASE | 2020年 / 323卷
基金：
中国国家自然科学基金;
关键词：
NEISSERIA-MENINGITIDIS; HELICOBACTER-PYLORI; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; PSEUDOMONAS-AERUGINOSA; SHIGELLA-FLEXNERI; VACCINE; PROTEIN; DELIVERY; SIZE;
D O I：
10.1016/j.jconrel.2020.04.031
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Outer membrane vesicles (OMVs) are produced by Gram-negative bacteria both in vitro and in vivo. OMVs are nano-sized spherical vehicles formed by lipid bilayer membranes and contain multiple parent bacteria-derived components. Based on the presence of bacterial antigens, pathogen-associated molecular patterns (PAMPs), adhesins, various proteins and the vesicle structure, OMVs have been developed for biomedical applications as bacterial vaccines, adjuvants, cancer immunotherapy agents, drug delivery vehicles, and anti-bacteria adhesion agents. In this review, we analyze the contributions of the structure and composition of OMVs to their applications, summarize the methods used to isolate and characterize OMVs, and highlight recent progress and future perspectives of OMVs in biomedical applications. © 2020 Elsevier B.V.
引用
收藏
页码：253 / 268
页数：16
相关论文
共 124 条
[1]   Bacterial outer membrane vesicles and vaccine applications [J].
Acevedo, Reinaldo ;
Fernandez, Sonsire ;
Zayas, Caridad ;
Acosta, Armando ;
Elena Sarmiento, Maria ;
Ferro, Valerie A. ;
Rosenqyise, Einar ;
Campal, Concepcion ;
Cardoso, Daniel ;
Garcia, Luis ;
Luis Perez, Jose .
FRONTIERS IN IMMUNOLOGY, 2014, 5
[2]   Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi [J].
Acevedo, Reinaldo ;
Callico, Adriana ;
Aranguren, Yisabel ;
Zayas, Caridad ;
Valdes, Yolanda ;
Perez, Oliver ;
Garcia, Luis ;
Ferro, Valerie A. ;
Luis Perez, Jose .
BMC IMMUNOLOGY, 2013, 14
[3]   GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence [J].
Adu-Bobie, J ;
Lupetti, P ;
Brunelli, B ;
Granoff, D ;
Norais, N ;
Ferrari, G ;
Grandi, G ;
Rappuoli, R ;
Pizza, M .
INFECTION AND IMMUNITY, 2004, 72 (04) :1914-1919
[4]   Gentamicin delivery to Burkholderia cepacia group IIIa strains via membrane vesicles from Pseudomonas aeruginosa PAO1 [J].
Allan, ND ;
Beveridge, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2962-2965
[5]   Affinity purification of bacterial outer membrane vesicles (OMVs) utilizing a His-tag mutant [J].
Alves, Nathan J. ;
Turner, Kendrick B. ;
DiVito, Kyle A. ;
Daniele, Michael A. ;
Walper, Scott A. .
RESEARCH IN MICROBIOLOGY, 2017, 168 (02) :139-146
[6]   Neutrophils in Homeostasis, Immunity, and Cancer [J].
Angel Nicolas-Avila, Jose ;
Adrover, Jose M. ;
Hidalgo, Andres .
IMMUNITY, 2017, 46 (01) :15-28
[7]  
[Anonymous], [No title captured]
[8]   Coincorporation of LpxL1 and PagL Mutant Lipopolysaccharides into Liposomes with Neisseria meningitidis Opacity Protein: Influence on Endotoxic and Adjuvant Activity [J].
Arenas, Jesus ;
van Dijken, Harry ;
Kuipers, Betsy ;
Hamstra, Hendrik Jan ;
Tommassen, Jan ;
van der Ley, Peter .
CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (04) :487-495
[9]   Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand [J].
Arnold, Richard ;
Galloway, Yvonne ;
McNicholas, Anne ;
O'Hallahan, Jane .
VACCINE, 2011, 29 (40) :7100-7106
[10]  
Asadi A, 2019, INFECTION, V47, P13, DOI 10.1007/s15010-018-1222-5
12345678910